Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation

Journal of Heart and Lung Transplantation

Volumn 23, Issue 3, 2004, Pages 277-283

  Haji, Showkat A ^a   Starling, Randall C ^a   Avery, Robin K ^a   Mawhorter, Steven ^a   Tuzcu, E Murat ^a   Schoenhagen, Paul ^a   Cook, Daniel J ^a   Ratliff, Norman B ^a   McCarthy, Patrick M ^a   Young, James B ^a   Yamani, Mohamad H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; CYCLOSPORIN A; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VIRUS RNA;

ACUTE GRAFT REJECTION; ARTICLE; B LYMPHOCYTE; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY BLOOD VESSEL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HAZARD ASSESSMENT; HEART TRANSPLANTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MORTALITY; ORGAN DONOR; PREDICTION; PRIORITY JOURNAL; RECIPIENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SERODIAGNOSIS; TREATMENT OUTCOME; VASCULAR DISEASE; VIREMIA;

CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TIME FACTORS; TISSUE DONORS;

EID: 12144287691     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(03)00148-7     Document Type: Article

References (23)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43
2. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 344:2001;1498-1503.
3. Vercellotti G.M. Microbes, inflammation and atherosclerosis will old pathology lessons guide new therapies? Trans Am Clin Climatol Assoc. 112:2001;. 215-213.
4. Valtonen V.V. Role of infections in atherosclerosis. Am Heart J. 138:1999;S431-433.
5. Grattan M.T., Moreno-Cabral C.E., Starnes V.A., et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 261:(24):1989;3561-3566.
6. Sorlie P.D., Adam E., Melnick S.L., et al. Cytomegalovirus/herpesvirus and carotid atherosclerosis the ARIC Study. J Med Virol. 42:1994;33-37.
7. Thom D.H., Gravston J.T., Siscovick D.S., et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 268:1992;68-72.
8. Zhu J., Quyyumi A.A., Norman J.E., et al. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis. 182:2000;1583-1587.
9. Tuzcu E.M., Kapadia S.R., Tutar E., et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults evidence from intravascular ultrasound. Circulation. 103:2001;2705-2710.
10. Kapadia S.R., Nissen S.E., Ziada K.M., et al. Impact of lipid abnormalities in development and progression of transplant coronary disease a serial intravascular ultrasound study. J Am Coll Cardiol. 38:(1):2001;206-213.
11. Cook D.J., Klingman L.L., Koo A.P., et al. Quantitative flow cytometry cross-matching for precise measurement of donor-specific alloreactivity. Transplant Proc. 26:(5):1994;2866-2867.
12. Ong J.P., Barnes D.S., Younossi Z.M., et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology. 30:(5):1999;1293-1298.
13. Younossi Z.M., Braun W.E., Protiva D.A., Gifford R.W. Jr, Straffon R.A. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation. 67:(2):1999;272-275.
14. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002;359:133-5
15. Valantine H.A., Gao S.Z., Menon S.G., et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis a post hoc analysis of a randomized, placebo-controlled study. Circulation. 100:(1):1999;61-66.
16. Shirali G.S., Ni J., Chinnock R.E., et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med. 344:(20):2001;1498-1503.
17. Avery R.K. Viral triggers of cardiac-allograft dysfunction. N Engl J Med. 344:(20):2001;1545-1547.
18. Agnello V., Chung R.T., Kaplan L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 327:1992;1490-1495.
19. Yang S.S., Tsai G., Wu C.H., Chen D.S. Circulating soluble intercellular adhesion molecule-1 in type C viral hepatitis. Hepatogastroenterology. 43:1996;575-581.
20. Lamprecht P., Moosig F., Gause A., et al. Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 60:(4):2001;385-390.
21. Rose E.A., Smith C.R., Petrossian G.A., et al. Humoral immune responses after cardiac transplantation correlation with fatal rejection and graft atherosclerosis. Surgery. 106:(2):1989;203-208.
22. Hosenpud J.D., Everett J.P., Morris T.E., et al. Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium. Circulation. 92:(2):1995;205-211.
23. Mehra M.R., Ventura H.O., Chambers R., et al. Predictive model to assess risk for cardiac allograft vasculopathy an intravascular ultrasound study. J Am Coll Cardiol. 26:(6):1995;1537-1544.